G 蛋白偶联受体靶向药物对癌症表型的非预期作用。
Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.
机构信息
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
出版信息
Trends Pharmacol Sci. 2020 Dec;41(12):1006-1022. doi: 10.1016/j.tips.2020.10.001. Epub 2020 Oct 22.
G protein-coupled receptors (GPCRs) are the most common class of therapeutic targets, accounting for ~35% of all FDA-approved drugs. Cancer patients receive numerous medications not only to combat cancer but also to alleviate pain, nausea, and anxiety, many of which target GPCRs. Emerging evidence has implicated GPCRs as drivers of cancer progression, therapeutic resistance, and metastasis. Therefore, the effects of commonly prescribed GPCR-targeted drugs must be reevaluated in the context of cancer. Epidemiological and experimental evidence indicate that widely used GPCR-targeted drugs may promote or inhibit cancer progression. It is crucial that we more fully understand the indirect effects of GPCR-targeted drugs on the cancer phenotype. This review summarizes recent advances in characterizing these interactions and highlights future research opportunities.
G 蛋白偶联受体（GPCRs）是最常见的治疗靶点类别，占所有获得美国食品和药物管理局（FDA）批准的药物的~35%。癌症患者不仅接受了许多用于治疗癌症的药物，还接受了许多用于缓解疼痛、恶心和焦虑的药物，其中许多药物针对的是 GPCRs。新出现的证据表明 GPCRs 是癌症进展、治疗耐药性和转移的驱动因素。因此，必须在癌症的背景下重新评估常用的针对 GPCR 的药物的效果。流行病学和实验证据表明，广泛使用的针对 GPCR 的药物可能促进或抑制癌症的进展。我们必须更全面地了解针对 GPCR 的药物对癌症表型的间接影响。这篇综述总结了最近在描述这些相互作用方面的进展，并强调了未来的研究机会。
Zotero 插件